MUChking about in IPF: identification of a novel goblet cell phenotype in pulmonary fibrosis

Colin D Bingle

The airway epithelium, extending from the nasal cavity through the trachea and bronchial passages to the alveoli, is a complex tissue that performs a multitude of vital functions. This epithelium is generally considered to be composed of two contiguous divisions: the proximal conducting airway regions that serve as a conduit for inhaled air and the distal gas exchanging regions of the peripheral lung. This simple view does not adequately reflect the range of specialised activities necessary for normal lung functions. These include not only the key function of gas exchange between the respiratory and circulatory systems but also the synthesis and secretion of components of the extracellular lining of the lungs, uptake and metabolism of secreted products and xenobiotics, fluid and electrolyte balance, and protection and repair of the epithelium following injury. Accomplishing these various tasks requires an array of differentiated epithelial cells capable of sustaining these functions in distinct portions of the lungs. The surface epithelium of the cartilaginous conducting airways is a pseudostratified columnar epithelium composed of ciliated, non-ciliated, goblet, neuroendocrine and basal cell types. Interspersed between the cartilaginous rings of the larger airways are the submucosal glands (SMGs). Airway SMGs are microscopically similar to other minor mucosal glands that underlie the epithelium of the nasal passages and oral cavity and it is now clear that they are a major source of the secretions that coat the airway epithelium. As the epithelium extends further down into the lungs the structure becomes a less complex cuboidal epithelial layer containing a mixture of ciliated and secretory cells until the epithelium in the alveolus is a mix of type I and type II pneumocytes intimately associated with the capillary bed.

There have been significant advances in the understanding of the molecular drivers of cellular commitment and differentiation of individual pulmonary cell types within the past 20 or so years. This area of investigation initially started through the study of cell-type restricted gene products, including the surfactant proteins (SP-A, B, C, and D) and clara cell secretory protein/uteroglobin (secretoglobin1A1). Subsequently, this led to the identification of transcription factors, including members of the FOX (forkhead box) and homeodomain containing protein families, including HNF-3/FOXA, FOXJ1 and NKX2.1/TTF-1, which not only regulated the cell type specific expression of lung restricted genes in adult cells but were also implicated in the regulation of aspects of lung development, and cell commitment and differentiation of distinct epithelial cell populations. This area of pulmonary biology is continuing to generate a rich study of cell-type restricted gene products, necessary for normal lung functions.1

The understanding of the molecular drivers of cellular commitment and differentiation but the utility of any such markers remains largely untested. While in many cases clinical and radiological features may allow a diagnosis, in many instances the pathologist remains key to the accurate diagnosis of IPF. On histopathological analysis, IPF lungs reveal what is known as the typical ‘usual interstitial pneumonia’ pattern of focal abnormalities including areas of epithelial hyperplasia, scarring with fibroblast foci and bronchiolisation of alveolar ducts, cysts and alveoli. Although much of the research on IPF has necessarily focused on the development of the characteristic fibrotic lesions, it is clear that major epithelial changes are found in this condition and indeed both the morphologically distinct processes are often present in different areas of the same lung. One of the most striking observations in this disease is the presence of a significant number of mucin-containing goblet cells within the bronchiolised epithelium. These cell types are normally absent from the distal lung epithelium. Mucin from these cells fills the honeycombed cysts. Although it seems likely that bronchiolar abnormalities are caused by changes in epithelial cell differentiation, the mechanisms governing this process are poorly understood. A number of studies in mouse models have begun to shed light on this process by showing that alveolar epithelial cell injury could be associated with the development of pulmonary fibrosis. Previous studies have implicated a number of molecular result in changes to the epithelium through the process of mucus cell metaplasia (eg, COPD). Importantly, these two processes are not mutually exclusive between particular diseases. The paper in this issue of Thorax by Plantier et al (see page 651) provides a novel and important insight into the altered phenotype of the remodelled bronchiolised epithelium found in the lungs of patients with idiopathic pulmonary fibrosis (IPF), a disease in which the significance of mucous cell metaplasia has not been so actively studied. IPF is an irreversible and progressive lung disease with limited life expectancy after diagnosis. The incidence of IPF appears to be growing with around 4000 patients per year being diagnosed in the UK. This is in part due to better diagnostic procedures. The cause of the condition remains elusive but it has both familial and environmental associations. Recently, there has been much activity directed towards the identification of novel molecular markers of disease classification and progression but the utility of any such markers remains largely untested.15

Correspondence to Dr Colin D Bingle, Reader in Respiratory Cell and Molecular Biology, Academic Unit of Respiratory Medicine, Department of Infection and Immunity, University of Sheffield, Halls Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, Sheffield, UK; c.d.bingle@sheffield.ac.uk

Thorax August 2011 Vol 66 No 8 647
pathways that underpin this process in IPF, but the nature of the goblet cells found in this disease is not well characterised. Plantier et al identify a novel phenotype of these cells and show that they stain strongly for one of the major gel-forming mucins, MUC5B, but not with the related protein MUC5AC. Additionally, they show that these goblet cells are negative for two of the transcription factors previously associated with airway goblet cell development, FOXA3 and SPDEF. Their data provide support for the growing concept that not all goblet cells are phenotypically identical. MUC5B and MUC5AC are major components of airway mucus and make a significant contribution to the abnormal viscous mucus seen in a number of chronic lung diseases. Normally, the major sites of MUC5B production are the SMGs whereas MUC5AC is the product of the goblet cell in the proximal airways. However, an increased SMG size and number has been associated with elevated mucus production in asthmatic and COPD airways. Ectopic MUC5B localisation has not previously been described in IFP and the data presented in this paper suggest that these cells have the characteristics of SMG goblet cells. To investigate these ectopic goblet cells further, the authors also studied the expression of neuregulins (NRGs) in these cases. NRGs are ligands for epidermal growth factor-related receptors and two alternatively spliced protein products of this protein, NRG1α and NRG1β, have been implicated in the production of goblet cells in vitro, with NRG1α in particular being associated with the generation of MUC5B-positive goblet cells. NRGs have previously been shown to play roles in many aspects of biology including lung development and lung cancer, but until now their role in chronic lung disease has not been studied. The data in the present paper show that NRG1α (but not NRG1β) is localised to squamous epithelium adjacent to regions of MUC5B expressing goblet cells in the honeycombed lung. This is particularly interesting in view of the increased incidence of lung cancer in IPF patients. Both proteins were also shown to be present in airway SMGs, further supporting the view that NRG1α is associated with MUC5B-positive mucous cell formation.

The fact that NRG1α is associated with IFP was also shown by the increase of the protein (but again not of NRG1β) in bronchoalveolar lavage fluid from a distinct group of patients with ‘early-stage’ IPF cases as compared with those having other interstitial lung diseases.

The data in this paper provide strong evidence that the mucous cell metaplasia seen in the bronchiolised epithelium of IPF cases is distinct from that seen in the airways of patients with COPD and asthma. It further suggests that a discrete set of molecular drivers are likely responsible for this phenotypic alteration. It remains to be seen if this is a genetic or environmental aspect of the disease. An increasing number of genetic associations have been described in IFP and recently interest has become focused on poly- morphisms located in the gel-forming mucin gene locus that includes MUC5A/C and MUC5B, located on chromosome 11p15.5, Whether the alterations of this protein (but again not of NRG1) that have been implicated in the production of MUC5AC is higher in the air space of patients with IPF , but the nature of the goblet cells found in this disease is not well characterised. Plantier et al identify a novel phenotype of these cells and show that they stain strongly for one of the major gel-forming mucins, MUC5B, but not with the related protein MUC5AC. Additionally, they show that these goblet cells are negative for two of the transcription factors previously associated with airway goblet cell development, FOXA3 and SPDEF. Their data provide support for the growing concept that not all goblet cells are phenotypically identical. MUC5B and MUC5AC are major components of airway mucus and make a significant contribution to the abnormal viscous mucus seen in a number of chronic lung diseases. Normally, the major sites of MUC5B production are the SMGs whereas MUC5AC is the product of the goblet cell in the proximal airways. However, an increased SMG size and number has been associated with elevated mucus production in asthmatic and COPD airways. Ectopic MUC5B localisation has not previously been described in IFP and the data presented in this paper suggest that these cells have the characteristics of SMG goblet cells. To investigate these ectopic goblet cells further, the authors also studied the expression of neuregulins (NRGs) in these cases. NRGs are ligands for epidermal growth factor-related receptors and two alternatively spliced protein products of this protein, NRG1α and NRG1β, have been implicated in the production of goblet cells in vitro, with NRG1α in particular being associated with the generation of MUC5B-positive goblet cells. NRGs have previously been shown to play roles in many aspects of biology including lung development and lung cancer, but until now their role in chronic lung disease has not been studied. The data in the present paper show that NRG1α (but not NRG1β) is localised to squamous epithelium adjacent to regions of MUC5B expressing goblet cells in the honeycombed lung. This is particularly interesting in view of the increased incidence of lung cancer in IPF patients. Both proteins were also shown to be present in airway SMGs, further supporting the view that NRG1α is associated with MUC5B-positive mucous cell formation. The fact that NRG1α is associated with IFP was also shown by the increase of the protein (but again not of NRG1β) in bronchoalveolar lavage fluid from a distinct group of patients with ‘early-stage’ IPF cases as compared with those having other interstitial lung diseases.

The data in this paper provide strong evidence that the mucous cell metaplasia seen in the bronchiolised epithelium of IPF cases is distinct from that seen in the airways of patients with COPD and asthma. It further suggests that a discrete set of molecular drivers are likely responsible for this phenotypic alteration. It remains to be seen if this is a genetic or environmental aspect of the disease. An increasing number of genetic associations have been described in IFP and recently interest has become focused on polymorphisms located in the gel-forming mucin gene locus that includes MUC5A/C and MUC5B, located on chromosome 11p15.5, Whether the alterations of this protein (but again not of NRG1) that have been implicated in the production of MUC5AC is higher in the air space of patients with IPF, but the nature of the goblet cells found in this disease is not well characterised. Plantier et al identify a novel phenotype of these cells and show that they stain strongly for one of the major gel-forming mucins, MUC5B, but not with the related protein MUC5AC. Additionally, they show that these goblet cells are negative for two of the transcription factors previously associated with airway goblet cell development, FOXA3 and SPDEF. Their data provide support for the growing concept that not all goblet cells are phenotypically identical. MUC5B and MUC5AC are major components of airway mucus and make a significant contribution to the abnormal viscous mucus seen in a number of chronic lung diseases. Normally, the major sites of MUC5B production are the SMGs whereas MUC5AC is the product of the goblet cell in the proximal airways. However, an increased SMG size and number has been associated with elevated mucus production in asthmatic and COPD airways. Ectopic MUC5B localisation has not previously been described in IFP and the data presented in this paper suggest that these cells have the characteristics of SMG goblet cells. To investigate these ectopic goblet cells further, the authors also studied the expression of neuregulins (NRGs) in these cases. NRGs are ligands for epidermal growth factor-related receptors and two alternatively spliced protein products of this protein, NRG1α and NRG1β, have been implicated in the production of goblet cells in vitro, with NRG1α in particular being associated with the generation of MUC5B-positive goblet cells. NRGs have previously been shown to play roles in many aspects of biology including lung development and lung cancer, but until now their role in chronic lung disease has not been studied. The data in the present paper show that NRG1α (but not NRG1β) is localised to squamous epithelium adjacent to regions of MUC5B expressing goblet cells in the honeycombed lung. This is particularly interesting in view of the increased incidence of lung cancer in IPF patients. Both proteins were also shown to be present in airway SMGs, further supporting the view that NRG1α is associated with MUC5B-positive mucous cell formation. The fact that NRG1α is associated with IFP was also shown by the increase of the protein (but again not of NRG1β) in bronchoalveolar lavage fluid from a distinct group of patients with ‘early-stage’ IPF cases as compared with those having other interstitial lung diseases. The data in this paper provide strong evidence that the mucous cell metaplasia seen in the bronchiolised epithelium of IPF cases is distinct from that seen in the airways of patients with COPD and asthma. It further suggests that a discrete set of molecular drivers are likely responsible for this phenotypic alteration. It remains to be seen if this is a genetic or environmental aspect of the disease. An increasing number of genetic associations have been described in IFP and recently interest has become focused on polymorphisms located in the gel-forming mucin gene locus that includes MUC5A/C and MUC5B, located on chromosome 11p15.5, Whether the alterations of this protein (but again not of NRG1) that have been implicated in the production of MUC5AC is higher in the air space of patients with IPF, but the nature of the goblet cells found in this disease is not well characterised. Plantier et al identify a novel phenotype of these cells and show that they stain strongly for one of the major gel-forming mucins, MUC5B, but not with the related protein MUC5AC. Additionally, they show that these goblet cells are negative for two of the transcription factors previously associated with airway goblet cell development, FOXA3 and SPDEF. Their data provide support for the growing concept that not all goblet cells are phenotypically identical. MUC5B and MUC5AC are major components of airway mucus and make a significant contribution to the abnormal viscous mucus seen in a number of chronic lung diseases. Normally, the major sites of MUC5B production are the SMGs whereas MUC5AC is the product of the goblet cell in the proximal airways. However, an increased SMG size and number has been associated with elevated mucus production in asthmatic and COPD airways. Ectopic MUC5B localisation has not previously been described in IFP and the data presented in this paper suggest that these cells have the characteristics of SMG goblet cells. To investigate these ectopic goblet cells further, the authors also studied the expression of neuregulins (NRGs) in these cases. NRGs are ligands for epidermal growth factor-related receptors and two alternatively spliced protein products of this protein, NRG1α and NRG1β, have been implicated in the production of goblet cells in vitro, with NRG1α in particular being associated with the generation of MUC5B-positive goblet cells. NRGs have previously been shown to play roles in many aspects of biology including lung development and lung cancer, but until now their role in chronic lung disease has not been studied. The data in the present paper show that NRG1α (but not NRG1β) is localised to squamous epithelium adjacent to regions of MUC5B expressing goblet cells in the honeycombed lung. This is particularly interesting in view of the increased incidence of lung cancer in IPF patients. Both proteins were also shown to be present in airway SMGs, further supporting the view that NRG1α is associated with MUC5B-positive mucous cell formation.
MUCking about in IPF: identification of a novel goblet cell phenotype in pulmonary fibrosis
Colin D Bingle

Thorax 2011 66: 647-648 originally published online April 17, 2011
doi: 10.1136/thx.2011.161307

Updated information and services can be found at:
http://thorax.bmj.com/content/66/8/647

These include:

References
This article cites 22 articles, 7 of which you can access for free at:
http://thorax.bmj.com/content/66/8/647#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/